Page last updated: 2024-11-12

6-hydroxybenzbromarone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6-hydroxybenzbromarone: metabolite M2 of benzbromarone [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10320994
CHEMBL ID1767079
SCHEMBL ID1288090
MeSH IDM0227886

Synonyms (20)

Synonym
6-hydroxybenzbromarone
chembl1767079 ,
(3,5-dibromo-4-hydroxyphenyl)(2-ethyl-6-hydroxy-benzofuran-3-yl)methanone
bdbm50342279
SCHEMBL1288090
FEXBXMFVRKZOOZ-UHFFFAOYSA-N
(3,5-dibromo-4-hydroxyphenyl)(2-ethyl-6-hydroxybenzofuran-3-yl)methanone ,
152831-00-0
HY-135774
(3,5-dibromo-4-hydroxyphenyl)-(2-ethyl-6-hydroxy-1-benzofuran-3-yl)methanone
CS-0113983
MS-27907
(3,5-dibromo-4-hydroxyphenyl)(2-ethyl-6-hydroxy-3-benzofuranyl)methanone
4m7nur5v9e ,
unii-4m7nur5v9e
methanone, (3,5-dibromo-4-hydroxyphenyl)(2-ethyl-6-hydroxy-3-benzofuranyl)-
AKOS040732340
PD193057
[3,5-bis(bromanyl)-4-oxidanyl-phenyl]-(2-ethyl-6-oxidanyl-1-benzofuran-3-yl)methanone
pkq ,

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" A single oral dose pharmacokinetic and pharmacodynamic trial of benzbromarone (100 mg) was performed in 20 healthy volunteers, which included 15 with CYP2C9*1/*1, 4 with CYP2C9*1/*3, and 1 with CYP2C9*3/*3."( Benzbromarone pharmacokinetics and pharmacodynamics in different cytochrome P450 2C9 genotypes.
Imai, H; Inui, N; Ishizaki, T; Katoh, Y; Misaka, S; Namiki, N; Ohashi, K; Shimada, K; Takeuchi, K; Uchida, S; Watanabe, H; Yamada, S, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 12Homo sapiens (human)IC50 (µMol)0.17930.02602.61527.3000AID1725622; AID593714; AID593715
Eyes absent homolog 3Homo sapiens (human)IC50 (µMol)27.20003.40005.85008.3000AID1411181; AID1622771
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
monoatomic ion transportSolute carrier family 22 member 12Homo sapiens (human)
response to xenobiotic stimulusSolute carrier family 22 member 12Homo sapiens (human)
urate transportSolute carrier family 22 member 12Homo sapiens (human)
cellular homeostasisSolute carrier family 22 member 12Homo sapiens (human)
cellular response to insulin stimulusSolute carrier family 22 member 12Homo sapiens (human)
urate metabolic processSolute carrier family 22 member 12Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 12Homo sapiens (human)
renal urate salt excretionSolute carrier family 22 member 12Homo sapiens (human)
organic anion transportSolute carrier family 22 member 12Homo sapiens (human)
double-strand break repairEyes absent homolog 3Homo sapiens (human)
chromatin remodelingEyes absent homolog 3Homo sapiens (human)
visual perceptionEyes absent homolog 3Homo sapiens (human)
anatomical structure morphogenesisEyes absent homolog 3Homo sapiens (human)
response to ionizing radiationEyes absent homolog 3Homo sapiens (human)
positive regulation of DNA repairEyes absent homolog 3Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandEyes absent homolog 3Homo sapiens (human)
cell differentiationEyes absent homolog 3Homo sapiens (human)
anatomical structure developmentEyes absent homolog 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
urate transmembrane transporter activitySolute carrier family 22 member 12Homo sapiens (human)
PDZ domain bindingSolute carrier family 22 member 12Homo sapiens (human)
protein tyrosine phosphatase activityEyes absent homolog 3Homo sapiens (human)
protein bindingEyes absent homolog 3Homo sapiens (human)
metal ion bindingEyes absent homolog 3Homo sapiens (human)
histone H2AXY142 phosphatase activityEyes absent homolog 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 12Homo sapiens (human)
membraneSolute carrier family 22 member 12Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 12Homo sapiens (human)
brush border membraneSolute carrier family 22 member 12Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 12Homo sapiens (human)
nucleusEyes absent homolog 3Homo sapiens (human)
nucleoplasmEyes absent homolog 3Homo sapiens (human)
cytoplasmEyes absent homolog 3Homo sapiens (human)
centrosomeEyes absent homolog 3Homo sapiens (human)
nucleusEyes absent homolog 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID593715Inhibition of human URAT1 expressed in human MDCK cells2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Developing potent human uric acid transporter 1 (hURAT1) inhibitors.
AID593713Inhibition of human URAT1 expressed in xenopus oocyte assessed as inhibition of [14C]-labelled urate uptake at 50 uM after 60 mins by liquid scintillation counting2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Developing potent human uric acid transporter 1 (hURAT1) inhibitors.
AID593714Inhibition of human URAT1 expressed in xenopus oocyte assessed as inhibition of [14C]-labelled urate uptake after 60 mins by liquid scintillation counting2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Developing potent human uric acid transporter 1 (hURAT1) inhibitors.
AID1725622Inhibition of URAT1 (unknown origin) transfected in dog MDCK cells assessed as inhibition of [14C]uric acid uptake by liquid scintillation counting method2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (25.00)18.2507
2000's0 (0.00)29.6817
2010's5 (62.50)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.97 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index5.17 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]